Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios

Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.

Financing

Two diagnostics companies announced they will be able to advance their cancer portfolio with new funding. Baltimore-based Personal Genome Diagnostics Inc. announced it raised $103m in a series C financing round and Cleveland Diagnostics announced it raised $17.4m in a series D round.

Personal Genome Diagnostics announced on 10 February it raised $103m in a new round of financing.

More from Business

More from Medtech Insight